INTRODUCTION
Integrin α v β 3 is overexpressed on activated endothelial cells during tumor-induced angiogenesis, but is absent on quiescent endothelial cells. Ruoslahti and co-workers found that this integrin interacts with the arginine-glycine-aspartic acid (RGD) amino acid sequence present on extracellular matrix proteins, such as vitronectin, fibrinogen and laminin (1) . Based on the RGD peptide sequence, series of small cyclic peptides, showing high and specific affinity for the α v β 3 integrin, have been developed (2) .
In the last few years, imaging of angiogenic processes using positron emission tomography (PET) or single photon emission computed tomography (SPECT) with radiolabeled RGD peptides has attracted considerable interest. These tracers have the potential to select patients who might benefit from treatment with antiangiogenic drugs as well as to monitor the therapeutic efficacy of integrin α v β 3 -targeted drugs.
The glycosylated cyclo(RGDfK) analog [ 18 F]galacto-RGD is of the α v β 3 integrin ligands the most intensely evaluated and studied in cancer patients (3) (4) (5) . Recently, another 18 Flabeled RGD peptide, 18 F-AH111585, has also been tested in preclinical studies and clinical trials (6) (7) (8) . Both tracers showed good pharmacokinetics and receptor-specific uptake, allowing non-invasive imaging of α v β 3 integrin expression. However, the synthesis of these tracers is complex and time-consuming with moderate yield, which hampers routine use in the clinical setting. 18 F is the most widely used radionuclide in PET and has excellent characteristics for peptide-based imaging, namely a half-life of 110 min that matches the pharmacokinetics of most peptides, and the low positron energy of 635 keV results in short ranges in tissue and excellent preclinical imaging resolution (<2 mm) (9) .
For radiofluorination of RGD peptides, a wide range of methods has been investigated. Chemoselective oxime formation allows high-yield two-step radiosynthesis of 18 F-labeled peptides via conjugation of 18 F-labeled aldehydes (e.g. 4-[ 18 F]fluorobenzaldehyde) with an aminooxy functionality in the peptide (10) . However, using 4-[ 18 F]fluorobenzaldehyde as the prosthetic group, invariably increased ligand lipophilicity, which often leads to unfavorable characteristics in vivo. It has since been shown that carbohydration is a powerful method to reduce lipophilicity of small radiolabeled peptides, resulting in improved pharmacokinetics of the radioligand (11) (12) (13) (14) . Recently, the direct conjugation of [ 18 F]FDG as a strategy for simultaneous carbohydration and labeling of a RGD peptide was investigated and resulted in good pharmacokinetics (15, 16) . However, this approach requires the use of carrier-free 18 F-FDG, necessitating reversed phase high-performance liquid chromatography (RP-HPLC) purification of 18 F-FDG before conjugation with the functionalized peptide, further increasing the length of time of preparation.
The Huisgen 1,3-dipolar cycloaddition reaction for radiofluorination of the dimeric RGD peptide E[c(RGDyK)] was explored and reported by Li and co-workers (17) . Although, click-labeled 18 F-FPTA-RGD 2 could be obtained with 27% non-decay-corrected labeling yield and exhibited favorable in vivo pharmacokinetics, this method requires azeotropic drying of the fluoride, resulting in a time-consuming multistep procedure. In addition, new 18 F-labeling strategies based on fluorine-silicon (18) (19) (20) (21) (22) (23) (24) , fluorine-boron (25) , and fluorine-phosphorus (26) 
RESULTS AND DISCUSSION

Radiolabeling
Al 18 F-labeled NODAGA-E-[c(RGDfK)] 2 was obtained with an overall labeling efficiency of 20%. A radiochemical purity of >98% was obtained after solid phase extraction on a hydrophilic-lipophilic balance (HLB) cartridge ( Figure 1A ). NODAGA-E-[c(RGDfK)] 2 was labeled with 68 Ga and 111 In with a labeling efficiency of 82% and 91% respectively. HLB cartridge purification of these increased the radiochemical purity to 85% and 95% respectively ( Figures 1B-C 
Octanol/Water partition coefficient
The lipophilicity of the Al 18 F-, 68 Ga-and 111 In-labeled NODAGA-E-[c(RGDfK)] 2 was determined using the octanol-water partition coefficients. The Log P octanol/PBS values of the lipophilic radiolabeled dimeric RGD peptides are given in Table 1 .
Competitive Binding Assay
The affinity of NODAGA-E-[c(RGDfK)] 2 and DOTA-E-[c(RGDfK)] 2 for integrin α v β 3 were determined in a solid-phase competitive binding assay (Figure 2 
Biodistribution Studies
The results of the biodistribution studies of Al 18 68 Ga-and 111 In-NODAGA-E-[c(RGDfK)] 2 also showed high retention in the kidneys, from which could be deduced that Al 18 F was stably chelated by NODAGA due to low uptake in the skeleton.
Discussion
In this study, we used the optimized Al 18 F-labeling method (27, 28) for the radiofluorination of NODAGA-E-[c(RGDfK)] 2 and evaluated this radiotracer in in vitro and in vivo studies. The in vitro and in vivo characteristics of this 18 F-labeled dimeric RGD peptide were directly compared with its 68 Ga-and 111 In-labeled counterparts.
Here, it was shown that Al 18 F-radiolabeled E-[c(RGDfK)] 2 via NODAGA increased the lipophilicity of the peptide. This was tested as it often leads to unfavorable characteristics in vivo. However the degree of lipophilicity did not alter the preferred route of excretion, which as determined from the biodistribution studies, was renal.
Using NODAGA allowed for the labeling of multiple isotopes and subsequent comparison of images obtained from PET and SPECT. For the labeling with 68 Ga (29) and 111 In, NODAGA was deemed a suitable chelator. However as shown in a study investigating the use of different chelators, NODAGA turned out not to be an adequate chelator for Al 18 F (30), although labeling efficiencies were similar to those found for Al 18 F-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-PRGD 2 (31 In a competitive binding assay using isolated integrin α v β 3 receptors, the IC 50 values of the NODAGA-conjugated and 1,4,7,10-tetra-azacylododecane-N,N',N",N"'-tetraaceticacid (DOTA)-conjugated RGD peptide were determined to be within the subnanomolar range and were not significantly different from each other. Recently, Knetsch and coworkers compared the IC 50 value of a NODAGA-and DOTA-conjugated RGD peptide (29) . In their study, the affinity of both tracers for α v β 3 integrin was also similar, showing that the replacement of the DOTA chelator with the NODAGA chelator has no influence on binding affinity and receptor-specific binding. It had already been demonstrated in previous studies that DOTA-conjugation to a monomeric RGD peptide had no influence on the affinity for integrin α v β 3 (34) , which is in line with our observation that NODAGA-E-[c(RGDfK)] 2 has a similar affinity to integrin α v β 3 as the DOTA-conjugated analogue.
In the subcutaneous SK-RC-52 xenograft model, Al 18 F-NODAGA-E-[c(RGDfK)] 2 showed specific tumor uptake (3.44 ± 0.20 %ID/g) at 2 h p.i. and good in vivo stability. This has not previously been determined for Al 18 F-labeled compounds via the NODAGA chelator. Tumor uptake of this Al 18 F-labeled RGD peptide was significantly lower than that of the 68 Ga-and 111 In-labeled analogs (5.78 ± 0.76 %ID/g and 4.99 ± 0.64 %ID/g, respectively). Nonetheless, at 2 h p.i. the tumor/muscle ratio uptake of Al 18 F-NODAGA-E-[c(RGDfK)] 2 obtained here was at least as high as those reported by Liu et al. and Lang et al. who determined the uptake of Al 18 F-NOTA-PRGD 2 in integrin α v β 3 -expressing U87MG glioma tumor model (35, 36) . Whether the fast radiofluorination outweighs the relatively low tumor uptake of Al 18 F-NODAGA-E-[c(RGDfK)] 2 depends on the situation and requirements for the use of a radiotracer in general. This study does however show that a vector molecule can be radiofluorinated with Al 18 F via NODAGA in a quick fashion and still maintain specific in vivo binding capabilities to its target.
Non-tumor tissues also showed specific uptake of Al 18 F-NODAGA-E-[c(RGDfK)] 2 , suggesting integrin α v β 3 expression in these tissues. Indeed, β 3 expression in colon, pancreas and lung tissues has previously been described for rodents as well as for humans (37) . Al 18 F-labeled NODAGA-E-[c(RGDfK)] 2 cleared rapidly from the blood, resulting in high tumor-to-blood ratios at 2 h p.i., namely 120 ± 30.
The Al 18 F method is a fast (45 min) radiofluorination strategy that does not affect the pharmacokinetics of the dimeric RGD peptide and the NODAGA chelator allows that the peptide can be labeled with 68 Ga and 111 In too. The commonly used method for efficient 18 F-labeling of peptides consists of two steps: first the preparation of 18 F-labeled synthons (prosthetic groups), followed by subsequent conjugation to a peptide or protein. In general, this fluorination is based on a nucleophilic substitution that requires timeconsuming azeotropic drying of the 18 F-fluoride-kryptofix complex. The total synthesis and formulation time for these methods ranges from 1 to 3 h. The Al 18 F-method used here however is based on a chelator-derivatized peptide making this labeling method easy and versatile.
CONCLUSIONS
The Al 18 F-method combines the ease of chelator-based radiolabeling methods with the advantages of 18 2 was radiolabeled with 18 F essentially as described by Laverman et al (38) . Briefly, a Chromafix cartridge with 2-6 GBq 18 F (BV Cyclotron VU, Amsterdam, The Netherlands) was washed with 3 mL of metal-free H 2 O. 18 F was eluted from the cartridge with 100 µL of 0.9% NaCl. Subsequently, 8.5 µL 2 mM AlCl 3 in 0.1 M sodium acetate buffer (pH 4) per GBq of 18 F was added to 18 F. Finally, 80 µL of this Al 18 F solution was added to 400 µL MeCN and 20 µL NODAGA-E-[c(RGDfK)] 2 in 0.5 M sodium acetate (pH 4.1; 5 µg/µL). The reaction mixture was heated at 100 °C for 15 min. The radiolabeled peptide was purified by RP-HPLC. Al 18 F-NODAGA-E-[c(RGDfK)] 2 -containing fractions were collected and diluted 10-fold with H 2 O and purified on an Oasis ® HLB cartridge to remove acetonitrile and TFA. In brief, the fraction was applied on the cartridge and the cartridge was washed with 3 × 1 mL H 2 O. The radiolabeled peptide was then eluted with 500 µL 50% EtOH. Before injection into mice, the EtOH was evaporated at 95 °C and the peptide was diluted with 0.5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) 7-9.1 µg, 1.6 -5.5 nmol) was used per mouse for the biodistribution or imaging studies, respectively.
Radiolabeling
F labeling-NODAGA-E-[c(RGDfK)]
68 Ga labeling-68 Ga was obtained from an 1850 MBq 68 Ge/ 68 Ga generator (IGG-100, Eckert & Ziegler, Berlin, Germany). The 68 Ga was eluted with 0.1 M HCl (Ultrapure, J.T. Baker, Deventer, The Netherlands) using an Econo Pump (Bio-Rad, Hercules, CA, USA) at 1 mL/min. Five 1 mL fractions were collected and an aliquot of the fraction containing the highest activity was used for radiolabeling. 68 Ga-labeled NODAGA-E-[c(RGDfK)] 2 was prepared by adding 40 µL of 2.5 M HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) to 10 µL of the peptide dissolved in 2.5 M HEPES (2 µg/µL). Then, 500 µL of the 68 Ga-eluate from the generator (200 MBq) was added. After 10 min at 100 °C, the 68 Galabeled peptide was purified on an Oasis ® HLB 1 cc (10 mg) cartridge as described above. Before injection into mice, the EtOH was evaporated at 95 °C and the peptide was diluted with 0.5% BSA/PBS. Finally, 0.4 MBq (0.1 µg, 0.06 nmol) or 3-10 MBq (0.9-3 µg, 0.54-1.8 nmol) was used per mouse for the biodistribution or imaging studies respectively. HPLC analysis-Quality control was performed using RP-HPLC on a C-18 (Onyx monolithic, 4.6 mm × 100 mm; Phenomenex) column. The column was eluted at a flow rate of 3 mL/min with a gradient of 97% buffer A at 0-5 min and 80% buffer A to 75 % buffer A at 5-20 min (buffer A, 0.1% v/v TFA in H 2 O; buffer B, 0.1% v/v TFA in acetonitrile). The preparations were analyzed on an Agilent 1200 system (Agilent Technologies, Palo Alto, CA, USA). Radioactivity was monitored using an in-line NaI radiodetector (Raytest GmbH, Straubenhardt, Germany). Elution profiles were analyzed using Gina-star software (Raytest GmbH, Straubenhardt, Germany). To obtain a radiochemical purity of >95%, Al 18 F-NODAGA-E-[c(RGDfK)] 2 was purified with the same HPLC system using the same conditions.
Octanol/Water partition coefficient
To 0.5 mL of the radiolabeled peptide (1 kBq) in PBS, pH 7.4, 0.5 mL octanol was added. After vigorous vortexing for 2 min at room temperature, the two layers were separated by centrifugation (100 × g, 5 min). 100 εL samples were taken from each layer and radioactivity was measured in a well-type gamma counter (Wallac Wizard 3", Perkin-Elmer, Waltham, MA). Log P values were calculated (n=3).
Cell culture
SK-RC-52 human renal carcinoma cells, stably expressing integrin α v β 3 , were cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal calf serum, 1% penicillin/ streptomycin and 1% glutamine (Invitrogen, Paisley, UK). Cells were maintained at 37 °C in a humidified 5% CO 2 atmosphere and routinely passaged using a 0.25% trypsin/EDTA solution (Invitrogen).
Solid-phase α v β 3 integrin binding assay
The affinity of DOTA-E-[c(RGDfK)] 2 and NODAGA-E-[c(RGDfK)] 2 for integrin α v β 3 was determined using a solid-phase competitive binding assay as described previously (39 
Biodistribution studies
In the right flank of 6-to 8-week-old female nude BALB/c mice, 2×10 6 SK-RC-52 cells in 200 µL medium was injected subcutaneously (s.c.). Two weeks after inoculation, when tumor sizes ranged from 60-90 mm 3 when measured by caliper, mice were injected intravenously (i.v.) with the Al 18 F-, 68 Ga-or 111 In-labeled RGD peptide (0.4 MBq) in 200 µL 0.5% BSA in PBS. Mice were euthanized by CO 2 /O 2 asphyxiation 2 h post-injection (p.i.) (n=3-5). Blood, tumor and the major organs and tissues were dissected, weighed and counted in a gamma counter. The percentage injected dose per gram (%ID/g) was determined for each sample. The receptor-mediated localization of the radiolabeled peptide was investigated by determining the biodistribution of the Al 18 F-, 68 Ga-or 111 In-labeled peptide in the presence of an excess (100-fold) unlabeled peptide (n=3-5).
All animal experiments were approved by the local Animal Welfare Committee in accordance with Dutch legislation and carried out in accordance to their guidelines.
microPET/CT and microSPECT/CT
In the right flank of 6-to 8-week-old female nude BALB/c mice, 2×10 6 
